Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data [PDF]
BackgroundAcute respiratory distress syndrome (ARDS) is a clinical syndrome with an extremely high mortality rate, and antiplatelet therapy is an important treatment approach.
Peng Zhang +5 more
doaj +2 more sources
Evaluation of the Rational use of Eptifibatide among Patients with Acute Coronary Syndrome Referred to Shahid Chamran Heart Hospital [PDF]
Objective: This cross-sectional descriptive study was conducted over 3 months (April–June 2025) among acute coronary syndrome (ACS) patients who received eptifibatide at Shahid Chamran Hospital, Isfahan.
Javad Amini +6 more
doaj +2 more sources
Administration of eptifibatide as rescue therapy during mechanical thrombectomy in acute ischemic stroke [PDF]
BackgroundThe success of the technical implementation of mechanical thrombectomy (MT) depends on many factors. Considering the experience of the interventional radiologist and the anatomical vascular differences of individual patients, it has technical ...
David Cernik +8 more
doaj +2 more sources
Adaptive Antithrombotic Strategy for Tandem Occlusion Stroke: Escalating Therapy After Thrombectomy and Stenting [PDF]
Background/Objectives: There is no consensus on standardized treatment algorithms for patients with acute ischemic stroke due to anterior circulation tandem occlusions.
Gregory Howaldt +11 more
doaj +2 more sources
Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience [PDF]
Background We evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
Shangsong Shi +4 more
doaj +2 more sources
Adjunctive Eptifibatide Administration in ACS Patients Undergoing Percutaneous Coronary Intervention: A Randomized Comparison of Bolus-only Versus Standard Therapy [PDF]
Background: Guidelines do not recommend routine glycoprotein IIb/IIIa inhibitors (GPIs), reserving them for high thrombotic-risk or bailout cases. Most acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are already
Fatemeh Baharvand +7 more
doaj +2 more sources
Acute Profound Thrombocytopenia Induced by Eptifibatide Causing Diffuse Alveolar Hemorrhage
Background. Eptifibatide is a glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitor which prevents platelet activation. The mechanism in which eptifibatide causes profound thrombocytopenia is poorly understood. One hypothesis suggests antibody-dependent
Gregory Byrd +5 more
doaj +1 more source
Application of eptifibatide injection in acute ischemic cerebrovascular disease [PDF]
Objective To evaluate the treatment effectiveness and safety of eptifibatide injection in the treatment of acute ischemic cerebrovascular disease (ICVD).
Mei Ni, Tian Liang
doaj +1 more source
Acute Stent Thrombosis Associated with Eptifibatide-Induced Profound Thrombocytopenia
Background. Eptifibatide is an inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that is commonly used in patients undergoing percutaneous coronary intervention (PCI). Case.
Amer Aljundi, Alaa Rahhal, Wafer Dabdoob
doaj +1 more source
Background: Glycoprotein IIb/IIIa inhibitor use in acute ischemic stroke (AIS) during mechanical thrombectomy (MT) and acute stenting and angioplasty is a topic consistently debated due to concerns over safety and efficacy.
Hari Movva +6 more
doaj +1 more source

